MA47676A - Polythérapie - Google Patents

Polythérapie

Info

Publication number
MA47676A
MA47676A MA047676A MA47676A MA47676A MA 47676 A MA47676 A MA 47676A MA 047676 A MA047676 A MA 047676A MA 47676 A MA47676 A MA 47676A MA 47676 A MA47676 A MA 47676A
Authority
MA
Morocco
Prior art keywords
polytherapy
Prior art date
Application number
MA047676A
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Arilla Maria Cristina Villellas
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA47676A publication Critical patent/MA47676A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA047676A 2017-03-01 2018-02-28 Polythérapie MA47676A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17158607 2017-03-01

Publications (1)

Publication Number Publication Date
MA47676A true MA47676A (fr) 2021-06-02

Family

ID=58192228

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047676A MA47676A (fr) 2017-03-01 2018-02-28 Polythérapie

Country Status (10)

Country Link
US (3) US11224596B2 (fr)
EP (2) EP4417262A3 (fr)
JP (2) JP7307682B2 (fr)
KR (2) KR20240053077A (fr)
CN (1) CN110831630A (fr)
BR (1) BR112019017901A2 (fr)
EA (1) EA201991997A1 (fr)
MA (1) MA47676A (fr)
PH (1) PH12019502002A1 (fr)
WO (1) WO2018158280A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
JP2022536043A (ja) * 2019-05-28 2022-08-12 塩野義製薬株式会社 シトクロムbc1阻害剤とクラリスロマイシン又はアジスロマイシン及びクロファジミンを組み合わせることを特徴とするマイコバクテリア感染症治療用医薬
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
IL328855A (en) * 2019-12-20 2026-08-01 Qurient Co Ltd Q203 Pharmaceutical Oral Dosage Form
EP4164645A4 (fr) * 2020-06-15 2024-07-10 The Global Alliance for TB Drug Development, Inc. Composition antibactérienne combinée et procédé de thérapie antibactérienne
CN112089713B (zh) * 2020-09-18 2022-02-22 中国科学院广州生物医药与健康研究院 一种基于吡唑并[1,5-a]吡啶类化合物的治疗结核分枝杆菌感染的药物组合物
WO2022119899A1 (fr) * 2020-12-02 2022-06-09 Shionogi & Co., Ltd. Médicament destiné au traitement d'une infection mycobactérienne, caractérisé par la combinaison d'un inhibiteur de cytochrome bc1 avec de la clarithromycine ou de l'azithromycine
CN115531388B (zh) * 2022-11-04 2024-03-22 首都医科大学附属北京胸科医院 治疗结核病的药物组合物
JP2026525955A (ja) 2023-07-18 2026-08-04 ヤンセン ファーマシューティカ エヌ.ベー. ベダキリン、プレトマニド又はデラマニド、及びシトクロムbc1阻害剤を含む、少なくとも三種の抗生物質の組み合わせ製品、並びにマイコバクテリア感染症の治療におけるそれらの使用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509673A (pt) 1994-11-15 1997-09-30 Upjohn Co Compostos e uso dos mesmos
US6090820A (en) 1995-05-11 2000-07-18 Pharmacia & Upjohn Company Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones
SI1527050T1 (sl) 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
CA2672960A1 (fr) 2006-12-20 2008-07-10 Schering Corporation Nouveaux inhibiteurs de jnk
CL2008001631A1 (es) 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
CN101965353B (zh) 2008-03-26 2014-12-17 丹诺医药(苏州)有限公司 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类
EP2353008A2 (fr) 2008-09-22 2011-08-10 Oregon Health and Science University Méthodes permettant de détecter une infection par le bacille de koch
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
IN2012DN04917A (fr) 2009-11-05 2015-09-25 Univ Notre Dame Du Lac
RU2576662C2 (ru) 2010-03-18 2016-03-10 Энститю Пастер Корея Противоинфекционные соединения
WO2012143796A2 (fr) 2011-04-21 2012-10-26 Institut Pasteur Korea Composés anti-inflammatoires
CA2845785A1 (fr) 2011-09-01 2013-03-07 Irm Llc Composes et compositions pouvant etre utilises en tant qu'inhibiteurs de la kinase c-kit
US8569283B2 (en) 2011-09-01 2013-10-29 Valentina Molteni Compounds and compositions as c-Kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
HRP20170411T1 (hr) 2012-03-02 2017-06-16 Genentech, Inc. Amido spirocilični amidni i sulfonamidni derivati
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
JP6483610B2 (ja) 2012-07-18 2019-03-13 ユニバーシティ オブ ノートルダム デュ ラック 5,5−ヘテロ芳香族抗感染症化合物
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
WO2015014993A2 (fr) 2013-08-02 2015-02-05 Institut Pasteur Korea Composés anti-infectieux
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
WO2015107482A1 (fr) 2014-01-17 2015-07-23 Piramal Enterprises Limited Association pharmaceutique pour traiter la tuberculose
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
CN107249691A (zh) * 2014-11-03 2017-10-13 加利福利亚大学董事会 用于肺结核治疗的多药疗法
MD3316969T2 (ro) 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
EP3472152A1 (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie

Also Published As

Publication number Publication date
BR112019017901A2 (pt) 2020-05-12
US20200016154A1 (en) 2020-01-16
JP7307682B2 (ja) 2023-07-12
JP2020509040A (ja) 2020-03-26
WO2018158280A1 (fr) 2018-09-07
EP3589323A1 (fr) 2020-01-08
PH12019502002A1 (en) 2020-06-29
EP3589323B1 (fr) 2024-04-03
JP2023061973A (ja) 2023-05-02
US11224596B2 (en) 2022-01-18
US11918575B2 (en) 2024-03-05
EP4417262A2 (fr) 2024-08-21
KR20240053077A (ko) 2024-04-23
KR20190121315A (ko) 2019-10-25
EP4417262A3 (fr) 2024-11-27
US20240325387A1 (en) 2024-10-03
EA201991997A1 (ru) 2020-01-22
CN110831630A (zh) 2020-02-21
US20220088012A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
DK3731771T3 (da) V462033dk00
EP3651772A4 (fr) Polythérapie anticancéreuse
EP3589248A4 (fr) Cryothérapies
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3634404C0 (fr) Inhibiteurs de magl à base de pyrazole
MA52090A (fr) Polythérapie
EP3697802A4 (fr) Analogues de saponine triterpénique
EP3588580A4 (fr) Diode schottky mos à tranchée
EP3515414A4 (fr) Polythérapie
DK3351526T3 (da) Diisopentylterephthalat
EP3721165C0 (fr) Charge militaire
EP3654852A4 (fr) Garrot
DK3568655T3 (da) Rekuperator
DK3571580T5 (da) Load-logical-and-shift-guarded-instruktion
EP3609520A4 (fr) Polythérapie ciblée
DK3612237T3 (da) Genterapi
EP3668507A4 (fr) Polythérapie
EP3611402A4 (fr) Servocylindre
EP3615471A4 (fr) Immunocapteur plasmo-photoélectronique
MA51576A (fr) Polythérapie
EP3669219C0 (fr) Réseau echelle
EP3714787A4 (fr) Biocapteur
EP3675891A4 (fr) Polythérapie anticancéreuse
EP3728590C0 (fr) Nouvelles thiophosphoramidites
DK3576686T3 (da) Brokbind